Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes

Hernández-Ávila, Mauricio; Torres‐Ibarra, Leticia; Stanley, Margaret; Salmerón, Jorge; Cruz-Valdéz, Aurelio; Muñóz, Núbia; Herrero, Rolando; Villaseñor-Ruíz, Ignacio F; Lazcano‐Ponce, Eduardo

doi:10.1080/21645515.2015.1058458

Cited by 33 publications

(26 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…41 The ACIP and ACS reviewed published and unpublished data from clinical trials in which boys and girls received 2 doses of HPV vaccine with an interval of at least 5 months. [42][43][44][45][46][47][48] Immunogenicity of 2 doses in individuals ages 9 to 14 years was found to be at least as high as immunogenicity of 3 doses in females ages 16 to 26 years across 7 studies. 41 Efficacy and cost-effectiveness data provide further support for a 2-dose schedule.…”

Section: Special Considerationsmentioning

confidence: 95%

Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening

Smith

Andrews

Brooks

et al. 2017

CA A Cancer J Clinicians

589

309

View full text Add to dashboard Cite

Answer questions and earn CME/CNE Each year, the American Cancer Society publishes a summary of its guidelines for early cancer detection, data and trends in cancer screening rates, and select issues related to cancer screening. In this issue of the journal, the authors summarize current American Cancer Society cancer screening guidelines, describe an update of their guideline for using human papillomavirus vaccination for cancer prevention, describe updates in US Preventive Services Task Force recommendations for breast and colorectal cancer screening, discuss interim findings from the UK Collaborative Trial on Ovarian Cancer Screening, and provide the latest data on utilization of cancer screening from the National Health Interview Survey. CA Cancer J Clin 2017;67:100-121. © 2017 American Cancer Society.

show abstract

Section: Special Considerationsmentioning

confidence: 95%

Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening

Smith

Andrews

Brooks

et al. 2017

CA A Cancer J Clinicians

589

309

View full text Add to dashboard Cite

show abstract

“…[35][36][37][38][39] The three doses required may be an obstacle in the implementation of HPV vaccination program in Ghana, however, two doses provide similar antibody levels as the three-dose schedule. 40,41 A two-dose regimen will increase HPV vaccine affordability and make for easier implementation. Because HPV vaccines are effective when given before sexual debut, the target age group should be young adolescents aged 10-14 years.…”

Section: Hpv Vaccinationmentioning

confidence: 99%

Recommendations for cervical cancer prevention and control in Ghana: public education and human papillomavirus vaccination

Nartey¹,

Hill²,

Amo‐Antwi³

et al. 2018

Ghana Medical Journal

View full text Add to dashboard Cite

SUMMARYGlobally, cervical cancer is a major public health issue causing increasing morbidity and mortality especially in lowand middle-income countries where preventive and control measures are lacking. In Ghana, it is the most common cancer among women. Approaches to reduce the incidence and mortality of the disease in Ghana have had little success due to lack of accurate data on the disease among other factors, to inform policies on prevention, early detection, diagnosis and treatment. Additionally, the lack of clear commitment, policy direction and resources has hindered the scale-up of some of the initiatives implemented to curb the cervical cancer situation in Ghana. In this paper, we make recommendations on cervical cancer education and human papillomavirus vaccination. A collaborative approach is needed involving both private and government organizations, health professionals and the general public. Public education on cervical cancer and HPV vaccination needs to be delivered through a mixture of systems including both healthcare facilities and outreach programs, involving teachers, youth groups, community members and professional bodies. The vaccination of adolescents aged 10-14 years using the nonavalent HPV vaccine will be important in reducing the incidence and mortality of cervical cancer in Ghana. The integration of public education on cervical cancer prevention, HPV vaccination and screening programs into both medical and public health services is critical in achieving high coverage of these programs. Funding: None

show abstract

“…This report is a sub-analysis of an open-label, nonrandomized clinical trial (NCT01717118)27 to evaluate the immunogenicity induced by the qHPV6/11/16/18 vaccine administered using an alternative (0-6 months) and traditional (0-2-6 months) vaccination schedules. 8 We made an extension of the original clinical trial, adding a booster dose at month 50 in the alternative schedule group. Group 1.…”

Section: Methodsmentioning

confidence: 99%

“…7 Recently, calls for the evaluation of alternative and more flexible vaccination scenarios have been made, as new data suggests that shorter schedules could be non-inferior to the three-dose schedule. 8,9 As in other low-and middle-income countries, Mexico requires flexible vaccine schedules to increase coverage. Alternative schedules have been studied in girls and women.…”

Section: Introductionmentioning

confidence: 99%

The effect of a booster dose of HPV tetravalent vaccine after 51 months: implications for extended vaccination schedules

Lazcano‐Ponce¹,

Carnalla²,

Barrientos‐Gutiérrez³

et al. 2018

Salud Publica Mex

Self Cite

View full text Add to dashboard Cite

The effect of a booster dose of HPV tetravalent vaccine after 51 months: implications for extended vaccination schedules Salud Publica Mex. 2018;60:666-673. AbstractObjective. To asses the non-inferiority between two different vaccination schedules one month after the administration of the third dose. Materials and methods. We evaluated the anti-HPV 16/18 antibody titers induced by quadrivalent HPV vaccine administered using two different schedules in girls 9 to 10-year-old girls: a traditional (0-2-6) and an alternative (0-6-50). Blood samples were collected at month 7, 21 and 51. Results. The antibody geometric mean titer ratios one month after the application of the third dose -month 51 for the alternative and month 7 for the traditional-were 1.55 for HPV16 (95%CI, 1.15-2.08) and 1.53 for HPV18 (95%CI, 1.12-2.09). The seropositive rate was above 99% in both groups. Conclusions. The application of an alternative 3-dose schedule in 9 to 10-year-old girls induces a non-inferior immune response compared to the standard one month after the last dose. Further research is needed to understand the minimal number of doses and their timing to provide the best coverage for HPV infection.

show abstract

Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes

Cited by 33 publications

References 35 publications

Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening

Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening

Recommendations for cervical cancer prevention and control in Ghana: public education and human papillomavirus vaccination

The effect of a booster dose of HPV tetravalent vaccine after 51 months: implications for extended vaccination schedules

Contact Info

Product

Resources

About